Orange Book product · Generic (ANDA)
ALBENDAZOLE
ALBENDAZOLE
At a glance
May 14, 2019
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
May 14, 2019
7 yr 2 mo ago
Today
Pharmaceutical detail
Active ingredient
ALBENDAZOLE
Strength
200MG
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
ANDA 211117
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of ALBENDAZOLE
- 1996ALBENZABrand (NDA)
NDA 020666 · IMPAX LABS INC
- 2024ALBENDAZOLEGeneric (ANDA)
ANDA 215652 · ALEMBIC
- 2021ALBENDAZOLEGeneric (ANDA)
ANDA 211034 · DR REDDYS
- 2021ALBENDAZOLEGeneric (ANDA)
ANDA 213435 · MSN
- 2020ALBENDAZOLEGeneric (ANDA)
ANDA 211636 · CHARTWELL RX
- 2019ALBENDAZOLEGeneric (ANDA)
ANDA 208094 · ACTAVIS ELIZABETH
- 2018ALBENDAZOLEGeneric (ANDA)
ANDA 208979 · ZYDUS PHARMS
- 2018ALBENDAZOLEGeneric (ANDA)
ANDA 210011 · STRIDES PHARMA
- 2018ALBENDAZOLEGeneric (ANDA)
ANDA 210434 · CIPLA LTD
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
